CAR-T Cell Therapy in Neuroimmune Diseases (Human Subjects)
CAR-T cell therapy has demonstrated preliminary clinical activity in certain patients suffering from refractory neuroimmune diseases, according to a systematic review. However, interpretations are limited by the small size and diversity of the patient populations involved.
- Tags
- #MSResearch
- Most relevant to
- —
Why it matters
This study highlights the potential of CAR-T cell therapy in neuroimmune conditions, indicating a need for further exploration. Understanding its effects could inform future treatment options.
What this does not prove
The findings are constrained by small and heterogeneous cohorts, limited follow-up, and a lack of controlled comparisons. Long-term safety and efficacy remain undefined.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Systematic review
- Participants / samples
- Not reported
- Randomised
- Yes
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-09-16
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
- Primary evidenceChimeric antigen receptor T-cell therapy in neuroimmune diseases: mechanistic rationale, clinical experience, and translational challenges. ↗DOI: 10.3389/fimmu.2026.1913956
Supporting passages (8)
study designThis narrative review integrates the mechanistic rationale, target selection, platform design, published human experience, and translational challenges of CAR-T cell therapy in neuroimmune diseases.
subjectsEvidence in multiple sclerosis and stiff-person syndrome is derived from individual reports, small early-phase studies, and conference data, whereas experience in other neuroimmune diseases remains limited to isolated reports or small case series.
randomizedMyasthenia gravis has the most diverse clinical experience, encompassing integrating CD19-, BCMA-, and dual CD19/BCMA-targeted products, together with a transient BCMA-targeted mRNA platform evaluated in a randomized, placebo-controlled phase 2b study.
peer reviewedJournal: Frontiers in immunology
findingsCAR-T cell therapy has shown preliminary clinical activity in selected patients with refractory neuroimmune diseases, but its comparative efficacy, durability, and long-term safety remain undefined.
limitationsAcross indications, interpretation is constrained by small and heterogeneous cohorts, limited follow-up, and the predominance of uncontrolled observations.
limitationsCAR-T cell therapy has shown preliminary clinical activity in selected patients with refractory neuroimmune diseases, but its comparative efficacy, durability, and long-term safety remain undefined.
publication datePublication date: 2026-09-16
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.